Profile data is unavailable for this security.
About the company
Dogwood Therapeutics, Inc., formerly Virios Therapeutics, Inc., is focused on the clinical development of three assets, Halneuron, IMC-1, and IMC-2. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor, to treat the neuropathic pain associated with chemotherapy treatment. Halneuron is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. IMC-2 (valacyclovir + celecoxib) is in Phase 2 development as a combination antiviral treatment for Long-COVID (LC). IMC-1 (famciclovir (FM) + celecoxib) is Phase 3 development ready as a combination antiviral treatment for FM. IMC-1 has been granted fast track designation by the FDA. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms.
- Revenue in -- (TTM)--
- Net income in --
- Incorporated--
- Employees--
- LocationDogwood Therapeutics Inc44 Milton AvenueALPHARETTA 30009United StatesUSA
- Websitehttps://www.virios.com/
More ▼
Mergers & acquisitions
| Acquired company | DWTX:NAQ since announced | Transaction value |
|---|---|---|
| Pharmagesic (Holdings) Inc | -- | 100.33m |
Data delayed at least 15 minutes, as of Oct 09 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bio Path Holdings Inc | 0.00 | -11.60m | 2.81m | 10.00 | -- | 1.95 | -- | -- | -17.91 | -17.91 | 0.00 | 0.5655 | 0.00 | -- | -- | 0.00 | -199.23 | -70.80 | -321.87 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
| Avenue Therapeutics Inc | 0.00 | -5.87m | 2.83m | 3.00 | -- | 0.4945 | -- | -- | -3.02 | -3.02 | 0.00 | 4.00 | 0.00 | -- | -- | 0.00 | -177.94 | -186.91 | -- | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -369.97k | 2.89m | 0.00 | -- | 7.14 | -- | -- | -0.0011 | -0.0011 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -78.67 | -696.88 | -85.20 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| Revelation Biosciences Inc | 0.00 | -15.90m | 3.02m | 9.00 | -- | 1.16 | -- | -- | -29.75 | -29.75 | 0.00 | 0.6939 | 0.00 | -- | -- | 0.00 | -112.35 | -- | -253.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
| Petros Pharmaceuticals Inc | 4.12m | -20.64m | 3.05m | 21.00 | -- | 0.3664 | -- | 0.7414 | -6.54 | -6.54 | 1.00 | 0.988 | 0.1529 | 0.6795 | 1.89 | 196,223.30 | -26.18 | -32.43 | -39.25 | -68.05 | 70.21 | 62.04 | -171.23 | -201.70 | 1.26 | -- | 0.4539 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Talis Biomedical Corp | 408.00k | -51.03m | 3.13m | 99.00 | -- | 0.0645 | -- | 7.68 | -28.02 | -28.02 | 0.224 | 26.69 | 0.0042 | -- | 1.53 | 4,121.21 | -52.13 | -68.18 | -57.23 | -74.22 | 95.10 | -- | -12,506.37 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
| Silexion Therapeutics Corp | 0.00 | -523.87k | 3.25m | 0.00 | -- | 0.5077 | -- | -- | -0.1403 | -0.1403 | 0.00 | 0.6559 | 0.00 | -- | -- | -- | -3.13 | -- | -3.77 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.96 | -- | -- | -- |
| Biostax Corp | 0.00 | -1.51m | 3.27m | -- | -- | -- | -- | -- | -0.0181 | -0.0181 | 0.00 | -0.0633 | 0.00 | -- | -- | -- | -395.44 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -4.04 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 507.20k | -4.14m | 3.27m | 5.00 | -- | 1.83 | -- | 6.45 | -0.6188 | -0.6188 | 0.074 | 0.224 | 0.1788 | -- | 16.01 | 101,440.00 | -146.02 | -- | -169.27 | -- | -- | -- | -816.72 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| Oragenics Inc | 7.47k | -19.52m | 3.32m | 5.00 | -- | -- | -- | 443.97 | -6.99 | -6.99 | 0.0023 | 0.2377 | 0.0013 | -- | -- | 1,494.00 | -349.31 | -97.60 | -451.26 | -106.24 | -- | -- | -261,261.60 | -36,169.75 | -- | -- | 0.00 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| GB Sciences Inc | 0.00 | -1.64m | 3.34m | 2.00 | -- | -- | -- | -- | -0.0041 | -0.0041 | 0.00 | -0.0131 | 0.00 | -- | -- | 0.00 | -597.54 | -31.80 | -- | -297.29 | -- | -- | -- | -- | -- | -6.49 | -- | -- | -- | -- | 60.24 | -- | -- | -- |
| Therapeutic Solutions International Inc | 91.38k | -2.00m | 3.42m | 3.00 | -- | 2.48 | -- | 37.41 | -0.0005 | -0.0005 | 0.00002 | 0.0003 | 0.0252 | 1.29 | 5.24 | 30,460.00 | -63.67 | -162.32 | -153.29 | -- | 65.18 | 67.79 | -2,530.31 | -2,391.85 | 0.3883 | -6.94 | 0.3164 | -- | -52.13 | 95.35 | 43.11 | -- | -- | -- |
Data as of Oct 09 2024. Currency figures normalised to Dogwood Therapeutics Inc's reporting currency: US Dollar USD
2.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 208.88k | 0.75% |
| Geode Capital Management LLCas of 30 Jun 2024 | 174.47k | 0.63% |
| McCollum Christoferson Group LLCas of 30 Jun 2024 | 57.00k | 0.21% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 52.83k | 0.19% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Jun 2024 | 30.00k | 0.11% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 24.04k | 0.09% |
| G1 Execution Services LLCas of 31 Mar 2024 | 23.36k | 0.08% |
| Regions Investment Management, Inc.as of 30 Jun 2024 | 20.07k | 0.07% |
| The Northwestern Mutual Life Insurance Co. (Invt Port)as of 31 Mar 2024 | 19.06k | 0.07% |
| Jane Street Capital LLCas of 31 Mar 2024 | 17.00k | 0.06% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
